Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus rating of “Buy” from the eleven ratings firms that are covering the company, MarketBeat reports. Eleven equities research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last year is $89.11.

Several analysts have recently commented on KROS shares. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating for the company. Finally, Bank of America cut their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th.

Insider Transactions at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics during the second quarter worth about $128,000. Ameritas Investment Partners Inc. grew its position in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares in the last quarter. Finally, Quest Partners LLC increased its stake in Keros Therapeutics by 23,945.0% in the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock valued at $220,000 after buying an additional 4,789 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 2.7 %

Shares of KROS opened at $58.04 on Tuesday. The firm’s fifty day simple moving average is $55.95 and its two-hundred day simple moving average is $51.93. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The stock has a market capitalization of $2.18 billion, a P/E ratio of -11.31 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The business had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter last year, the firm posted ($1.27) EPS. As a group, research analysts predict that Keros Therapeutics will post -4.88 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.